NCT04677452UnknownPhase 1
An Open-Label Phase 1 Dose Exploration Study of JWCAR129, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory Multiple Myeloma
The First Affiliated Hospital of Soochow University1 site in 1 country24 target enrollmentStarted: December 1, 2020Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Sponsor
- Enrollment
- 24
- Locations
- 1
- Primary Endpoint
- Incidence and severity of adverse events
Study Overview
Brief Summary
This is an open-label, Phase 1 dose exploration study to evaluate the safety and tolerability and to determine recommended Phase 2 dose(s) of JWCAR129, a CAR T-cell product that targets B-cell maturation antigen (BCMA), in adult subjects with relapsed and/or refractory multiple myeloma.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •18 years old and above.
- •Signed the Informed Consent Form.
- •Diagnosis of multiple myeloma (MM) with relapsed and/or refractory disease. Subjects must have received at least 3 prior anti-myeloma treatment regimens (note: induction with or without bone marrow transplant and with or without maintenance therapy is considered one regimen). Subjects must be refractory to the last anti-myeloma treatment regimen prior to entering the study.
- •Autologous hematopoietic stem cell transplantation.
- •A regimen that included an immunomodulatory agent (eg, thalidomide, lenalidomide, pomalidomide) and a proteasome inhibitor (eg, bortezomib, carfilzomib, ixazomib), either alone or in combination. Subjects must have undergone at least 2 consecutive cycles of treatment for each regimen unless progressive disease was the best response to the regimen.
- •Anti-CD38 (eg, daratumumab) as part of a combination regimen or as a monotherapy.
- •Subjects who were not candidates to receive one or more of the above treatments (ie, contraindicated) are eligible; the reason for not receiving treatment must be clearly documented in the case report form.
- •Subjects must have measurable disease.
- •Subject must be willing to provide fresh bone marrow biopsy samples during Screening (and prior to study treatment, if required).
- •Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- •Adequate renal, bone marrow, hepatic, pulmonary, and cardiac function
Exclusion Criteria
- •Subjects with known active or history of CNS involvement by malignancy
- •Subjects with solitary plasmacytoma; active or history of plasma cell leukemia (PCL); Waldenstrom's macroglobulinemia; Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal plasmaproliferative disorder, Skin changes (POEMS) syndrome; or symptomatic amyloidosis
- •History of another primary malignancy that has not been in remission for at least 3 years. The following are exempt from the 3-year limit: non-melanoma skin cancer, curatively treated localized prostate cancer, cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on Pap smear, and in situ breast cancer that has been completely resected.
- •Require systemic immunosuppressive therapies (eg, calcineurin inhibitors, methotrexate, mycophenolate, rapamycin, thalidomide, immunosuppressive antibodies such as anti-IL-6 or anti-IL-6 receptor [IL-6R])
- •Prior CAR T-cell or other genetically-modified T-cell therapy
- •Prior treatment with a BCMA-targeted agent
- •History or presence of clinically relevant CNS pathology such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis
- •Untreated or active infection at time of initial screening, at the time of leukapheresis, within 72 hrs before lymphodepletion, or 5 days before JWCAR129 infusion.
- •History of any of the following cardiovascular conditions within 6 months of initial screening: Class III or IV heart failure as defined by the New York Heart Association (NYHA), myocardial infarction, unstable angina, uncontrolled or symptomatic atrial arrhythmias, any ventricular arrhythmias, or other clinically significant cardiac disease
- •History of severe immediate hypersensitivity reaction to any of the protocol-mandated or recommended agents used in this study
- •Allogeneic hematopoietic stem cell transplantation.
Outcomes
Primary Outcomes
Incidence and severity of adverse events
Time Frame: 2 years
Proportion of subjects with adverse events overall and by severity grade
Incidence of dose-limiting toxicities (DLTs)
Time Frame: 28 days
Proportion of subjects with adverse events meeting DLT criteria
Incidence and severity of clinically significant laboratory abnormalities
Time Frame: 2 years
Proportion of subjects with clinically significant laboratory abnormalities overall and by severity grade
Secondary Outcomes
- Overall response rate(2 years)
- Duration of persistence(2 years)
- CR rate(2 years)
- Tmax(2 years)
- Cmax(2 years)
- AUC(2 years)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Terminated
Phase 1
A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid TumorsLiver Cancer, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Cervical Cancer, MSI-H Colorectal CancerNCT05427396Shanghai Junshi Bioscience Co., Ltd.31
Completed
Phase 1
A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid TumorsMelanomaRenal CarcinomaUrothelial CarcinomaNCT04773951Shanghai Junshi Bioscience Co., Ltd.47
Completed
Phase 1
Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid TumorsMalignant Solid TumourNCT01337505ImmunityBio, Inc.24
Completed
Phase 1
A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.Advanced Solid TumorsNCT03545971Innovent Biologics (Suzhou) Co. Ltd.53
Completed
Phase 1
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 VaccineCOVID-19NCT04545749United Biomedical Inc., Asia60